AbbVie Glioblastoma Drug Misses Primary Endpoint

Date : 05/17/2019 @ 2:31PM
Source : Dow Jones News
Stock : Abbvie Inc. (ABBV)
Quote : 68.54  0.29 (0.42%) @ 1:00AM

AbbVie Glioblastoma Drug Misses Primary Endpoint

AbbVie Inc. (NYSE:ABBV)
Historical Stock Chart

3 Months : From Apr 2019 to Jul 2019

Click Here for more AbbVie Inc. Charts.

By Chris Wack


AbbVie (ABBV) said Friday that its phase 3 study of its glioblastoma drug depatuxizumab mafodotin didn't meet its primary endpoint.

The biopharmaceutical company said its Intellance-1 study of depatuxizumab mafodotin in patients with newly diagnosed glioblastoma failed to achieve its overall survival objective, and demonstrated no survival benefit for patients receiving Depatux-M at an interim analysis.

Abbvie said an independent data monitoring committee recommended the study be stopped due to lack of survival benefit for patients receiving Depatux-M compared with the placebo when added to the standard regimen of radiation and temozolomide.

AbbVie said no new safety findings were observed, and enrollment in all ongoing Depatux-M studies has been halted.

The Intellance-1 trial was conducted in collaboration with the RTOG Foundation, an independent, non-profit cancer research organization.

Glioblastoma, also known as glioblastoma multiforme, is an aggressive type of cancer that can occur in the brain or spinal cord.


Write to Chris Wack at


(END) Dow Jones Newswires

May 17, 2019 09:16 ET (13:16 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest ABBV Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.